All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Emerging ADC Data and Combination Strategies Are Set to Redefine First-Line TNBC Management

November 12th 2025

Joyce O'Shaughnessy, MD, discusses ways that data with sacituzumab govitecan and Dato-DXd may shift treatment standards for patients with mTNBC.

Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma

November 12th 2025

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma

November 12th 2025

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC

November 12th 2025

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling

November 12th 2025

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

Oncology Experts and AI Advocates Explain the Evolving Role of AI in Insurance Appeals

November 12th 2025

Using AI to automate oncology insurance prior authorization submissions could help lighten the load for health care professionals and speed access to care.

Sequential CAR T-Cell Therapy and ASCT Yields Durable Remissions in Ph-Negative B-ALL

November 12th 2025

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

NALIRIFOX Expands Frontline Options in Metastatic Pancreatic Cancer

November 11th 2025

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma

November 11th 2025

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting

November 11th 2025

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

FDA Approves OncoMate MSI Dx as Companion Diagnostic for Pembrolizumab/Lenvatinib in MSS Endometrial Cancer

November 11th 2025

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Detalimogene Produces 63% CR Rate in BCG-Unresponsive NMIBC with CIS

November 11th 2025

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA Sarcoma

November 11th 2025

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

Oncology Experts Debate the Potential for AI to Improve Timely Access to Care

November 11th 2025

Incorporating AI into daily workflows may allow oncology professionals to save time on insurance denial claims and re-allocate time back into patient care.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma

November 11th 2025

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC

November 10th 2025

Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.

Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy

November 10th 2025

Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.

Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management

November 10th 2025

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

November 10th 2025

The NCCN has released their updated Clinical Practice Guidelines in Oncology for NSCLC.

Bezuclastinib Plus Sunitinib Shows PFS Benefit in Second-Line GIST

November 10th 2025

The phase 3 PEAK trial met its primary PFS end point with bezuclastinib plus sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumors.